JP2002515453A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002515453A5 JP2002515453A5 JP2000549285A JP2000549285A JP2002515453A5 JP 2002515453 A5 JP2002515453 A5 JP 2002515453A5 JP 2000549285 A JP2000549285 A JP 2000549285A JP 2000549285 A JP2000549285 A JP 2000549285A JP 2002515453 A5 JP2002515453 A5 JP 2002515453A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- pharmaceutical composition
- ribavirin
- patient
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010047761 Interferon-alpha Proteins 0.000 description 16
- 102000006992 Interferon-alpha Human genes 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 9
- 229960000329 ribavirin Drugs 0.000 description 9
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 102100040018 Interferon alpha-2 Human genes 0.000 description 4
- 108010079944 Interferon-alpha2b Proteins 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 3
- 208000020403 chronic hepatitis C virus infection Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7956698A | 1998-05-15 | 1998-05-15 | |
| US09/079,566 | 1998-05-15 | ||
| PCT/US1999/007037 WO1999059621A1 (en) | 1998-05-15 | 1999-05-13 | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011085606A Division JP2011173898A (ja) | 1998-05-15 | 2011-04-07 | 慢性Ｃ型肝炎感染を有する、抗ウイルス処置を受けていない患者における、リバビリンおよびインターフェロンαを含む併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002515453A JP2002515453A (ja) | 2002-05-28 |
| JP2002515453A5 true JP2002515453A5 (https=) | 2006-06-15 |
| JP5281726B2 JP5281726B2 (ja) | 2013-09-04 |
Family
ID=22151354
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000549285A Expired - Lifetime JP5281726B2 (ja) | 1998-05-15 | 1999-05-13 | 慢性Ｃ型肝炎感染を有する、抗ウイルス処置を受けていない患者における、リバビリンおよびインターフェロンαを含む併用療法 |
| JP2011085606A Withdrawn JP2011173898A (ja) | 1998-05-15 | 2011-04-07 | 慢性Ｃ型肝炎感染を有する、抗ウイルス処置を受けていない患者における、リバビリンおよびインターフェロンαを含む併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011085606A Withdrawn JP2011173898A (ja) | 1998-05-15 | 2011-04-07 | 慢性Ｃ型肝炎感染を有する、抗ウイルス処置を受けていない患者における、リバビリンおよびインターフェロンαを含む併用療法 |
Country Status (22)
| Country | Link |
|---|---|
| EP (3) | EP0956861B1 (https=) |
| JP (2) | JP5281726B2 (https=) |
| KR (1) | KR100694345B1 (https=) |
| CN (1) | CN1230198C (https=) |
| AR (1) | AR019551A1 (https=) |
| AT (1) | ATE216591T1 (https=) |
| AU (2) | AU766597B2 (https=) |
| BR (1) | BR9910505A (https=) |
| CA (1) | CA2331823A1 (https=) |
| CZ (1) | CZ300540B6 (https=) |
| DE (1) | DE69901321T2 (https=) |
| DK (1) | DK0956861T3 (https=) |
| ES (1) | ES2172288T3 (https=) |
| HU (1) | HU230432B1 (https=) |
| IL (3) | IL139220A0 (https=) |
| MY (1) | MY129244A (https=) |
| NO (1) | NO330715B1 (https=) |
| NZ (1) | NZ507621A (https=) |
| PT (1) | PT956861E (https=) |
| SK (1) | SK288038B6 (https=) |
| TW (1) | TWI277424B (https=) |
| WO (1) | WO1999059621A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| AR021876A1 (es) * | 1998-12-18 | 2002-08-07 | Schering Corp | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado |
| KR20030032908A (ko) * | 1999-12-23 | 2003-04-26 | 아이씨엔 파마슈티컬스, 인코포레이티드 | Ｌ-누클레오시드, ｌ-누클레오티드 및 이들의 유사체에대한 조성물 및 방법 |
| JP4536194B2 (ja) * | 2000-02-17 | 2010-09-01 | 大日本住友製薬株式会社 | 安定な注射用製剤 |
| EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| KR20080021797A (ko) | 2000-05-26 | 2008-03-07 | 이데닉스(케이만)리미티드 | 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물 |
| EP1326594A2 (en) * | 2000-10-18 | 2003-07-16 | Schering Corporation | Ribavirin-pegylated interferon alfa hcv combination therapy |
| AU2002330154A1 (en) | 2001-09-28 | 2003-04-07 | Centre National De La Recherche Scientifique | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| IL161889A0 (en) * | 2001-11-09 | 2005-11-20 | Biomedicines Inc | Method for treating diseases with omega interferon |
| EP2261250B1 (en) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin fusion proteins |
| PL374781A1 (en) | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| BR0312271A (pt) | 2002-06-28 | 2007-11-06 | Idenix Cayman Ltd | compostos, composições e seus usos para o tratamento de infecções por flaviviridae |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation |
| RU2005121904A (ru) | 2002-12-12 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 2`-разветвленных нуклеозидов |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| RU2005133093A (ru) * | 2003-03-28 | 2006-07-27 | Фармассет, Инк. (Us) | Соединения для лечения флавивирусных инфекций |
| JP2006528679A (ja) * | 2003-04-01 | 2006-12-21 | インターミューン インコーポレイテッド | コロナウイルス感染症及びサースを治療するための組成物及び方法 |
| US20070026014A1 (en) * | 2003-04-17 | 2007-02-01 | Ares Trading S.A. | Interferon beta in severe acute respiratory syndrome (sars) |
| EP2345657A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| EP1641485A4 (en) * | 2003-06-09 | 2009-06-24 | Genome Inst Of Singapore | INHIBITION OF SARS CORONAVIRUS INFECTION USING ANTIVIRAL DRUGS CLINICALLY TESTED |
| JP2007501806A (ja) * | 2003-08-13 | 2007-02-01 | ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー | ウィルス感染を治療する方法 |
| AR045870A1 (es) * | 2003-10-11 | 2005-11-16 | Vertex Pharma | Terapia de combinacion para la infeccion de virus de hepatitis c |
| CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| AU2005285045B2 (en) | 2004-09-14 | 2011-10-13 | Gilead Sciences, Inc. | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| TWI437990B (zh) * | 2004-10-29 | 2014-05-21 | Vertex Pharma | Vx-950之醫藥用途 |
| AP2907A (en) | 2006-01-09 | 2014-05-31 | Romark Lab Lc | Viral hepatitis treatment |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| EP2175865A4 (en) | 2007-07-25 | 2012-01-11 | Biolex Therapeutics Inc | INTERFERON DRUG PRODUCTS WITH CONTROLLED RELEASE AND TREATMENT OF HCV INFECTIONS THEREWITH |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| RU2369403C1 (ru) * | 2008-05-22 | 2009-10-10 | Сергей Юрьевич Родионов | Способ лечения хронических вирусных гепатитов |
| KR20110098849A (ko) | 2008-12-23 | 2011-09-01 | 파마셋 인코포레이티드 | 뉴클레오시드 유사체 |
| PT2376088T (pt) | 2008-12-23 | 2017-05-02 | Gilead Pharmasset Llc | Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída |
| SG194404A1 (en) | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| EP2427213B1 (en) | 2009-05-08 | 2015-04-01 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| PT2609923T (pt) | 2010-03-31 | 2017-08-30 | Gilead Pharmasset Llc | Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo |
| JP2013542206A (ja) * | 2010-10-05 | 2013-11-21 | ノバルティス アーゲー | Ｃ型肝炎ウイルス感染症の新規治療 |
| AU2011336632B2 (en) | 2010-11-30 | 2015-09-03 | Gilead Pharmasset Llc | Compounds |
| KR20190060879A (ko) * | 2011-03-02 | 2019-06-03 | 제롬 쉔타그 | 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단 |
| PL2709613T5 (pl) | 2011-09-16 | 2020-12-14 | Gilead Pharmasset Llc | Metody leczenia hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| PT2950786T (pt) | 2013-01-31 | 2020-03-03 | Gilead Pharmasset Llc | Formulação de combinação de dois compostos antivirais |
| EA201690473A1 (ru) | 2013-08-27 | 2017-03-31 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Комбинированный состав двух противовирусных соединений |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US4492537A (en) | 1982-12-10 | 1985-01-08 | Awerkamp John B | Fluid-operated oil or water well pump |
| US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質，その製造法および中間体 |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| KR960705579A (ko) * | 1993-11-10 | 1996-11-08 | 에릭에스. 딕커 | 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates) |
| US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| PT858343E (pt) * | 1995-11-02 | 2004-07-30 | Schering Corp | Terapia por infusao continua de uma dose baixa de citoquina |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| CA2298543A1 (en) | 1997-08-13 | 1999-02-25 | James Barry | Loading and release of water-insoluble drugs |
| DK1136075T3 (da) * | 1997-09-21 | 2003-04-28 | Schering Corp | Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion |
-
1999
- 1999-05-13 CA CA002331823A patent/CA2331823A1/en not_active Abandoned
- 1999-05-13 HU HU0103423A patent/HU230432B1/hu unknown
- 1999-05-13 IL IL13922099A patent/IL139220A0/xx unknown
- 1999-05-13 SK SK1710-2000A patent/SK288038B6/sk not_active IP Right Cessation
- 1999-05-13 MY MYPI99001891A patent/MY129244A/en unknown
- 1999-05-13 AT AT99303729T patent/ATE216591T1/de active
- 1999-05-13 EP EP99303729A patent/EP0956861B1/en not_active Expired - Lifetime
- 1999-05-13 PT PT99303729T patent/PT956861E/pt unknown
- 1999-05-13 DE DE69901321T patent/DE69901321T2/de not_active Expired - Lifetime
- 1999-05-13 CZ CZ20004177A patent/CZ300540B6/cs not_active IP Right Cessation
- 1999-05-13 AU AU38600/99A patent/AU766597B2/en not_active Withdrawn - After Issue
- 1999-05-13 ES ES99303729T patent/ES2172288T3/es not_active Expired - Lifetime
- 1999-05-13 TW TW088107774A patent/TWI277424B/zh not_active IP Right Cessation
- 1999-05-13 JP JP2000549285A patent/JP5281726B2/ja not_active Expired - Lifetime
- 1999-05-13 CN CNB998085960A patent/CN1230198C/zh not_active Expired - Lifetime
- 1999-05-13 WO PCT/US1999/007037 patent/WO1999059621A1/en not_active Ceased
- 1999-05-13 KR KR1020007012784A patent/KR100694345B1/ko not_active Expired - Lifetime
- 1999-05-13 DK DK99303729T patent/DK0956861T3/da active
- 1999-05-13 EP EP01130613A patent/EP1213029A1/en not_active Withdrawn
- 1999-05-13 EP EP10181927A patent/EP2305287A1/en not_active Withdrawn
- 1999-05-13 BR BR9910505-5A patent/BR9910505A/pt not_active Application Discontinuation
- 1999-05-14 AR ARP990102303A patent/AR019551A1/es unknown
-
2000
- 2000-10-18 NZ NZ507621A patent/NZ507621A/xx not_active IP Right Cessation
- 2000-10-23 IL IL139220A patent/IL139220A/en not_active IP Right Cessation
- 2000-11-14 NO NO20005755A patent/NO330715B1/no not_active IP Right Cessation
-
2005
- 2005-10-10 AU AU2005220271A patent/AU2005220271B9/en not_active Expired
-
2010
- 2010-07-27 IL IL207259A patent/IL207259A/en not_active IP Right Cessation
-
2011
- 2011-04-07 JP JP2011085606A patent/JP2011173898A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002515453A5 (https=) | ||
| AU750026B2 (en) | Product comprising at least a double stranded RNA combined with at least an antiviral agent | |
| SK155997A3 (en) | Use of ribavirin and interferon alpha for the treatment of hepatitis c | |
| NZ502740A (en) | Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
| JP2009504157A5 (https=) | ||
| WO2000037110A3 (en) | Ribavirin-pegylated interferon alfa induction hcv combination therapy | |
| RU2007105354A (ru) | Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv) | |
| RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
| US20110165119A1 (en) | Telaprevir dosing regimen | |
| Zein | Interferons in the management of viral hepatitis | |
| JP2007501806A5 (https=) | ||
| US20150258167A1 (en) | New Treatments of Hepatitis C Virus Infection | |
| HK1048951A1 (zh) | 与PEG-IFN-α结合的霉酚酸酯MOFETIL | |
| KR20140007927A (ko) | C형 간염 바이러스 감염을 치료하기 위한 알리스포리비르 | |
| AU2006339220B2 (en) | Pharmaceutical composition for treatment of blood clotting disorder | |
| WO2006131566A3 (en) | Oral ribavirin pharmaceutical compositions | |
| James | Ribavirin approved for hepatitis C combination treatment | |
| Cerrato | Zinc may enhance interferon's effects | |
| Sarin | What should we advise about adjunctive therapies, including herbal medicines, for hepatitis C? | |
| Stoia | Hepatitis C: new treatment overview | |
| James | Crixivan (Indinavir): Three doses daily, not two, in most regimens | |
| Horváth et al. | The Role and the Possibilities of Natural Interferon Treatment for Chronic Hepatitis C: Our Experiences with Natural Interferon Treatment for Patients Debarred from Combined Antiviral Therapy due to the STOP Rule | |
| US20160235808A1 (en) | Treatment of Hepatitis C Virus Infection with Alisporivir | |
| Tcherveniakova et al. | High percentage of sustained response in IV drug abusers with acute viral hepatitis C treated with interferon | |
| Andreone | Clinical impact of lamivudine resistance in patients with HB |